CymaBay Therapeutics, Inc. (NASDAQ:CBAY) traded at $6.56 at last check on Monday, Sep 14, making an upward move of 13.3% on its previous day’s price.

Looking at the stock we see that its previous close was $5.79 and the beta (5Y monthly) reads 1.64 with the day’s price range being $5.90 – 6.78. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, CBAY has a high of $7.09 and a low of $1.21. The company’s stock has gained about 13.79% over that past 30 days.

CymaBay has a market cap of $458.54 Million and is expected to release its quarterly earnings report on August 10, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the CBAY stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.16, with the EPS growth for the year raised at -$0.71 for 2020 and -$1.01 for next year. These figures represent -0.51% and at 0.42% growth in EPS for the two years respectively.

On the other hand, looking at the outlook for the CBAY stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 10 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the CymaBay Therapeutics, Inc. (CBAY) stock as a Hold, while 10 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the CBAY stock currently stands at 0, and the current price level is 5.14% off its SMA20 and 29.89% from its 50-day simple moving average. The RSI (14) is pointing at 60.55 while the volatility over the past week is 9.8% and drops to 8.23% over the past one month. The beta value is 1.64, while the average true range (ATR) is currently pointing at 0.54. The average price target for the stock over the next 12 months is $12.8, with the estimates having a low of $8 and a high of $20. These price ends are 21.95% and +204.88% off the current price level respectively, although investors could be excited at the prospect of a +98.17% if the CBAY share price touches on the median price of $13.

Let’s briefly compare CymaBay (CBAY) stock to its peers. We find that today’s price change of +13.3% and +14.09% over the past 12 months for CBAY competes that of Dr. Reddy’s Laboratories Ltd (RDY), which has seen its stock price fall -0.35% in the latest trading session and is +53.92% over the last one year. Another of its peers Teva Pharmaceutical Industries Ltd (TEVA) has climbed 3.41% today, and is +14.48% up over the past year, while Mylan NV Ord Shs (MYL) is also up 13.3% yet its price remains in the green at 14.09% over the same period. Dr. has a P/E ratio of 39.04 compared to CymaBay’s 0 and Teva’s 3030. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.

Coming back to CymaBay Therapeutics, Inc. (NASDAQ:CBAY), we note that the average 3-month trading volume was 3.67 Million, while that of the preceding 10-day period stands at 1.38 Million. Current shares outstanding are 68.89 Million.

According to data from Thomson Reuters, insiders hold 0.62% of the company’s shares while institutions hold 88.01%. The data shows that short shares as of August 30, 2020, stood at 6.35 Million at a short ratio of 1.12. This represents a 9.22% Short interest in Shares outstanding on August 30, 2020. Shares short dropped in August from the previous month at 9.81 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +234.69% up in year-to-date price movement.